Dai Qigang, Liang Qi, Hu Yuemei, Meng Fanyue, Li Jingxin, Hou Lihua, Zhou Hailong, Chu Kai, Hu Xiaokui, Tang Rong, Wang Wenjuan, Hu Jialei, Huang Haodi, Li Zhen, Yang Shuqi, Zhu Fengcai
a Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , China.
b Beijing Institute of Biotechnology , Beijing , China.
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-6. doi: 10.1080/21645515.2017.1288328. Epub 2017 Feb 22.
A phase-1 clinical trial aimed to assess the safety and immunogenicity of the type-5 adenovirus vector based Ebola vaccine (Ad5-EBOV) was conducted in China. To provide more evidence for the safety evaluation and dose-selection, an exploratory sub-study using a wireless automatic temperature measuring platform was done based on the phase-1 clinical trial. The main aim of the sub-study was to obtain more information about the occurrence of fever and detect the potential associated factors, second was to assess the feasibility of the temperature measuring platform in vaccine clinical trials. Temperature data of 3 treatment groups all presented a rising tendency during the first 6 hours after vaccination, the incidence of elevated temperature and possible associated factors were analyzed. For the incidence of elevated temperature, no marked dose-response relationship was found in 6 hours with wireless thermometers; the information from mercury thermometers showed that the grade-1 fever proportion peaked at 6 hours and there was no difference between groups, while grade-2 fever proportion peaked at 24 hours and was significantly higher in high-dose group than those in the other 2 groups. Significant differences were found between sex groups (males vs. female, incidence rate ratios (IRR) = 2.93 and 7.62 for any-grade, grade-2 fever respectively, P<0.001); a decline in grade-2 fever incidence was found with the increasing age groups (IRR = 0.78, P = 0.003) and body mass index (BMI, IRR = 0.67, P<0.001) .Our findings show that the dose-dependent manner between fever and the dose of Ad5-EBOV in this study might emerge after 6 hours, and which is slight and transient. Wireless thermometers secured on the skin surface are not suitable for a long time (longer than 6 hours) measurement, new methods for temperature monitoring, like ear temperature measurement, should be tested in the further research.
一项旨在评估基于5型腺病毒载体的埃博拉疫苗(Ad5-EBOV)安全性和免疫原性的1期临床试验在中国开展。为了为安全性评估和剂量选择提供更多证据,在1期临床试验的基础上,利用无线自动温度测量平台开展了一项探索性子研究。该子研究的主要目的是获取更多关于发热发生情况的信息并检测潜在相关因素,其次是评估温度测量平台在疫苗临床试验中的可行性。分析了3个治疗组在接种疫苗后前6小时的温度数据变化趋势、体温升高的发生率及可能的相关因素。对于体温升高的发生率,无线体温计在6小时内未发现明显的剂量反应关系;水银体温计信息显示,1级发热比例在6小时达到峰值且组间无差异,而2级发热比例在24小时达到峰值且高剂量组显著高于其他2组。性别组间存在显著差异(男性与女性,任何级别、2级发热的发病率比(IRR)分别为2.93和7.62,P<0.001);2级发热发生率随年龄组增加而下降(IRR = 0.78,P = 0.003),且随体重指数(BMI)增加而下降(IRR = 0.67,P<0.001)。我们的研究结果表明,本研究中发热与Ad5-EBOV剂量之间的剂量依赖关系可能在6小时后出现,且这种关系轻微且短暂。固定在皮肤表面的无线体温计不适合长时间(超过6小时)测量,新的体温监测方法,如耳部体温测量,应在进一步研究中进行测试。